{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:30Z","timestamp":1793898270836,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90566-3","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:50:47Z","timestamp":1740538247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Mengjiao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"90566_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/ijmm.2022.5098","volume":"49","author":"F Ghorbaninezhad","year":"2022","unstructured":"Ghorbaninezhad, F. et al. Tumor necrosis factor\u2013\u03b1 in systemic lupus erythematosus: structure, function and therapeutic implications (review). Int. J. Mol. Med. 49, 43. https:\/\/doi.org\/10.3892\/ijmm.2022.5098 (2022).","journal-title":"Int. J. Mol. Med."},{"key":"90566_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3238\/arztebl.m2022.0067","volume":"119","author":"I Kremenevski","year":"2022","unstructured":"Kremenevski, I., Sander, O., Sticherling, M., Raithel, M. & LastName, F. M. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch. Arzteblatt Int. 119, 88\u201395. https:\/\/doi.org\/10.3238\/arztebl.m2022.0067 (2022).","journal-title":"Dtsch. Arzteblatt Int."},{"key":"90566_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal, B. B., Gupta, S. C. & Kim, J. H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119, 651\u2013665. https:\/\/doi.org\/10.1182\/blood-2011-04-325225 (2012).","journal-title":"Blood"},{"key":"90566_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/apt.15097","volume":"49","author":"UN Shivaji","year":"2019","unstructured":"Shivaji, U. N. et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 49, 664\u2013680. https:\/\/doi.org\/10.1111\/apt.15097 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"90566_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","volume":"16","author":"M P\u00e9rez-De-Lis","year":"2017","unstructured":"P\u00e9rez-De-Lis, M. et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin. Drug Saf. 16, 1255\u20131271. https:\/\/doi.org\/10.1080\/14740338.2017.1372421 (2017).","journal-title":"Expert Opin. Drug Saf."},{"key":"90566_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"C Eriksson","year":"2005","unstructured":"Eriksson, C., Engstrand, S., Sundqvist, K-G. & Rantap\u00e4\u00e4-Dahlqvist, S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann. Rheum. Dis. 64, 403\u2013407. https:\/\/doi.org\/10.1136\/ard.2004.024182 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"90566_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1573397115666190506152729","volume":"16","author":"MA Aghdashi","year":"2020","unstructured":"Aghdashi, M. A., Khadir, M. & Dinparasti-Saleh, R. Antinuclear Antibodies and lupus-like manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis patients at 4 months\u2019 follow-up after treatment with Infliximab and Etanercept. Curr. Rheumatol. Rev. 16, 61\u201366. https:\/\/doi.org\/10.2174\/1573397115666190506152729 (2020).","journal-title":"Curr. Rheumatol. Rev."},{"key":"90566_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1586\/1744666X.4.2.275","volume":"4","author":"F Atzeni","year":"2008","unstructured":"Atzeni, F. & Sarzi-Puttini, P. Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev. Clin. Immunol. 4, 275\u2013280. https:\/\/doi.org\/10.1586\/1744666X.4.2.275 (2008).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"90566_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.nephro.2010.05.003","volume":"6","author":"M Sacqu\u00e9p\u00e9e","year":"2010","unstructured":"Sacqu\u00e9p\u00e9e, M. et al. Tivollier J-M. active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis. Nephrol. Ther. 6, 537\u2013540. https:\/\/doi.org\/10.1016\/j.nephro.2010.05.003 (2010).","journal-title":"Nephrol. Ther."},{"key":"90566_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","volume":"78","author":"L Arnaud","year":"2019","unstructured":"Arnaud, L. et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann. Rheum. Dis. 78, 504\u2013508. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214598 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"90566_CR11","volume-title":"Practical aspects of signal detection in pharmacovigilance","author":"CIOMS Working Group","year":"2010","unstructured":"CIOMS Working Group. Practical Aspects of Signal Detection in Pharmacovigilance (Council for International Organizations of Medical Sciences, 2010)."},{"key":"90566_CR12","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng, L., Xiao, K., Ottaviani, S., Stebbing, J. & Wang, Y-J. A real-world disproportionality analysis of FDA adverse event reporting System (FAERS) events for baricitinib. Expert Opin. Drug Saf. 19, 1505\u20131511. https:\/\/doi.org\/10.1080\/14740338.2020.1799975 (2020).","journal-title":"Expert Opin. Drug Saf."},{"key":"90566_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","volume":"37","author":"PM Tregunno","year":"2014","unstructured":"Tregunno, P. M., Fink, D. B., Fernandez-Fernandez, C., L\u00e1zaro-Bengoa, E. & Nor\u00e9n, G. N. Performance of probabilistic method to detect duplicate individual case safety reports. Drug Saf. 37, 249\u2013258. https:\/\/doi.org\/10.1007\/s40264-014-0146-y (2014).","journal-title":"Drug Saf."},{"key":"90566_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40264-022-01210-2","volume":"45","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Anti-tumor necrosis factor-alpha therapy and hypoglycemia: a real-world pharmacovigilance analysis. Drug Saf. 45, 951\u2013959. https:\/\/doi.org\/10.1007\/s40264-022-01210-2 (2022).","journal-title":"Drug Saf."},{"key":"90566_CR15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","volume":"154","author":"H Chen","year":"2024","unstructured":"Chen, H., Yang, G. & Ma, J. Ocular toxicity associated with anti-HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database. Int. J. Cancer. 154, 1616\u20131625. https:\/\/doi.org\/10.1002\/ijc.34848 (2024).","journal-title":"Int. J. Cancer"},{"key":"90566_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff, J. S. et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther. 82, 157\u2013166. https:\/\/doi.org\/10.1038\/sj.clpt.6100258 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"90566_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"90566_CR18","doi-asserted-by":"publisher","unstructured":"Ps, A., Z, C., Cl, C. & Bc, T. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin. Drug Saf. 15, https:\/\/doi.org\/10.1517\/14740338.2016.1167184 (2016).","DOI":"10.1517\/14740338.2016.1167184"},{"key":"90566_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1517\/14740338.2014.915938","volume":"13","author":"Y Hou","year":"2014","unstructured":"Hou, Y. et al. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin. Drug Saf. 13, 853\u2013857. https:\/\/doi.org\/10.1517\/14740338.2014.915938 (2014).","journal-title":"Expert Opin. Drug Saf."},{"key":"90566_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF03256733","volume":"22","author":"Y Chen","year":"2008","unstructured":"Chen, Y. et al. Comparison of sensitivity and Timing of Early Signal Detection of Four Frequently Used Signal Detection Methods: an empirical study based on the US FDA adverse event reporting System Database. Pharm. Med. 22, 359\u2013365. https:\/\/doi.org\/10.1007\/BF03256733 (2008).","journal-title":"Pharm. Med."},{"key":"90566_CR21","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1192\/j.eurpsy.2023.2474","volume":"66","author":"C Chen","year":"2023","unstructured":"Chen, C., Zhou, R., Fu, F. & Xiao, J. Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur. Psychiatry J. Assoc. Eur. Psychiatr. 66, e99. https:\/\/doi.org\/10.1192\/j.eurpsy.2023.2474 (2023).","journal-title":"Eur. Psychiatry J. Assoc. Eur. Psychiatr"},{"key":"90566_CR22","unstructured":"21 CFR 314.80. -- Postmarketing reporting of adverse drug experiences. https:\/\/www.ecfr.gov\/current\/title-21\/part-314\/section-314.80 [Accessed May 4, 2024]."},{"key":"90566_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai, Y. et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J. Immunother Cancer. 7, 286. https:\/\/doi.org\/10.1186\/s40425-019-0754-2 (2019).","journal-title":"J. Immunother Cancer"},{"key":"90566_CR24","doi-asserted-by":"publisher","first-page":"R545","DOI":"10.1186\/ar1715","volume":"7","author":"M De Bandt","year":"2005","unstructured":"De Bandt, M. et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. 7, R545\u2013551. https:\/\/doi.org\/10.1186\/ar1715 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"90566_CR25","doi-asserted-by":"publisher","unstructured":"Wetter, D. A. & Davis, M. D. P. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 84 979\u2013984. (2009). https:\/\/doi.org\/10.4065\/84.11.979","DOI":"10.4065\/84.11.979"},{"key":"90566_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Med. (Baltim). 86, 242\u2013251. https:\/\/doi.org\/10.1097\/MD.0b013e3181441a68 (2007).","journal-title":"Med. (Baltim)."},{"key":"90566_CR27","doi-asserted-by":"publisher","unstructured":"R P-A, M P-L, M. R. C. Biologics-induced autoimmune diseases. Curr. Opin. Rheumatol. 25, https:\/\/doi.org\/10.1097\/BOR.0b013e32835b1366 (2013).","DOI":"10.1097\/BOR.0b013e32835b1366"},{"key":"90566_CR28","unstructured":"Mengdi, S., Han, X., Xudong, M., Zhang, H. & Li, L. Perioperative Management of Tumor Necrosis Factor Alpha Inhibitors. Herald Med. 1\u201325 (2024)."},{"key":"90566_CR29","doi-asserted-by":"publisher","first-page":"103332","DOI":"10.1016\/j.autrev.2023.103332","volume":"22","author":"L De Stefano","year":"2023","unstructured":"De Stefano, L. et al. Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun. Rev. 22, 103332. https:\/\/doi.org\/10.1016\/j.autrev.2023.103332 (2023).","journal-title":"Autoimmun. Rev."},{"key":"90566_CR30","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.13699\/j.cnki.1001-6821.2017.20.026","volume":"33","author":"X Xuecai","year":"2017","unstructured":"Xuecai, X., Lu, C., Xingxian, L. & Feng, W. Status of research on drug induced antibodies followingtreatment withtumor necrosis factor-a inhibitors. Chin. J. Clin. Pharmacol. 33, 2089\u20132092. https:\/\/doi.org\/10.13699\/j.cnki.1001-6821.2017.20.026 (2017).","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"90566_CR31","doi-asserted-by":"publisher","first-page":"e000314","DOI":"10.1136\/rmdopen-2016-000314","volume":"3","author":"M Jani","year":"2017","unstructured":"Jani, M. et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open. 3, e000314. https:\/\/doi.org\/10.1136\/rmdopen-2016-000314 (2017).","journal-title":"RMD Open."},{"key":"90566_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10067-007-0728-5","volume":"27","author":"M Benucci","year":"2008","unstructured":"Benucci, M., Saviola, G., Baiardi, P., Cammelli, E. & Manfredi, M. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin. Rheumatol. 27, 91\u201395. https:\/\/doi.org\/10.1007\/s10067-007-0728-5 (2008).","journal-title":"Clin. Rheumatol."},{"key":"90566_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","volume":"13","author":"M Piga","year":"2014","unstructured":"Piga, M. et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun. Rev. 13, 873\u2013879. https:\/\/doi.org\/10.1016\/j.autrev.2014.05.005 (2014).","journal-title":"Autoimmun. Rev."},{"key":"90566_CR34","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00063-007-1104-6","volume":"102","author":"H Haake","year":"2007","unstructured":"Haake, H., K\u00f6neke, J., Amann, K., vom Dahl, J. & Janssen, U. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med. Klin. Munich Ger. 1983. 102, 852\u2013857. https:\/\/doi.org\/10.1007\/s00063-007-1104-6 (2007).","journal-title":"Med. Klin. Munich Ger. 1983"},{"key":"90566_CR35","first-page":"740","volume":"32","author":"A Mor","year":"2005","unstructured":"Mor, A., Bingham, C. O., Barisoni, L., Lydon, E. & Belmont, H. M. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J. Rheumatol. 32, 740\u2013743 (2005).","journal-title":"J. Rheumatol."},{"key":"90566_CR36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0961203308100560","volume":"18","author":"A Neradov\u00e1","year":"2009","unstructured":"Neradov\u00e1, A., Stam, F., van den Berg, J. G. & Bax, W. A. Etanercept-associated SLE with lupus nephritis. Lupus 18, 667\u2013668. https:\/\/doi.org\/10.1177\/0961203308100560 (2009).","journal-title":"Lupus"},{"key":"90566_CR37","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","volume":"20","author":"MB Stokes","year":"2005","unstructured":"Stokes, M. B. et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol. Dial Transpl. Off Publ Eur. Dial Transpl. Assoc. - Eur. Ren. Assoc. 20, 1400\u20131406. https:\/\/doi.org\/10.1093\/ndt\/gfh832 (2005).","journal-title":"Nephrol. Dial Transpl. Off Publ Eur. Dial Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"90566_CR38","first-page":"447","volume":"43","author":"TM Yahya","year":"2013","unstructured":"Yahya, T. M., Dhanyamraju, S., Harrington, T. M. & Prichard, J. W. Spontaneous resolution of lupus nephritis following withdrawal of etanercept. Ann. Clin. Lab. Sci. 43, 447\u2013449 (2013).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"90566_CR39","doi-asserted-by":"publisher","first-page":"9989729","DOI":"10.1155\/2021\/9989729","volume":"2021","author":"A Fonseca","year":"2021","unstructured":"Fonseca, A., Sunny, J. & Felipez, L. M. Antitumor Necrosis factor-alpha (TNF-\u03b1) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn\u2019s Disease. Case Rep. Pediatr. 2021, 9989729. https:\/\/doi.org\/10.1155\/2021\/9989729 (2021).","journal-title":"Case Rep. Pediatr."},{"key":"90566_CR40","doi-asserted-by":"crossref","unstructured":"Harnett, D. T., Chandra-Sekhar, H. B. & Hamilton, S. F. Drug-Induced Lupus Erythematosus Presenting With Cardiac Tamponade: A Case Report and Literature Review. Can. J. Cardiol. (2014).","DOI":"10.1016\/j.cjca.2013.11.011"},{"key":"90566_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jcpt.12586","volume":"43","author":"V Dipasquale","year":"2018","unstructured":"Dipasquale, V., Gramaglia, S. M. C., Catena, M. A. & Romano, C. Pericarditis during infliximab therapy in paediatric ulcerative colitis. J. Clin. Pharm. Ther. 43, 107\u2013109. https:\/\/doi.org\/10.1111\/jcpt.12586 (2018).","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90566-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90566-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:50:54Z","timestamp":1740538254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90566-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90566"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90566-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6838"}}